COVID-19 Infection among Elite Football Players: A Nationwide Prospective Cohort Study.
COVID-19
incidence
professional footballers
relative risk
transmission
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
19 Apr 2022
19 Apr 2022
Historique:
received:
14
03
2022
revised:
07
04
2022
accepted:
14
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Little is known about the risk of COVID-19 infection among footballers. We aimed to investigate the incidence and characteristics of COVID-19 infection among footballers. In total, 480 football players of Super League Greece and 420 staff members participated in a prospective cohort study, which took place from May 2020 to May 2021. Nasopharyngeal swabs were collected from footballers and staff members weekly. All samples (n = 43,975) collected were tested using the reverse transcriptase polymerase chain reaction (RT-PCR) test for the detection of “SARS-CoV-2”. In total, 190 positive cases (130 among professional football players and 60 among staff) were recorded. Out of the 190 cases that turned positive, 64 (34%) cases were considered as symptomatic, and 126 (66%) cases were asymptomatic. The incidence rate of a positive test result for footballers was 0.57% (confidence interval (CI) 0.48−0.68%) and for staff members it was 0.27% (CI 0.20%, 0.34%), respectively. Footballers recorded a twofold increased risk of COVID-19 infection in comparison to staff members (relative risk = 2.16; 95% CI = 1.59−2.93; p-value < 0.001). No significant transmission events were observed during the follow-up period. We found a low incidence of COVID-19 infection among professional footballers over a long follow-up period. Furthermore, the implementation of a weekly diagnostic testing (RT-PCR) was critical to break the transmission chain of COVID-19, especially among asymptomatic football players and staff members.
Identifiants
pubmed: 35632390
pii: vaccines10050634
doi: 10.3390/vaccines10050634
pmc: PMC9144666
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Acta Biomed. 2016 Sep 13;87(2):117-20
pubmed: 27648991
Br J Sports Med. 2022 Feb;56(3):158-164
pubmed: 34663570
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
Br J Sports Med. 2021 Oct;55(19):1092-1098
pubmed: 33589470
BMJ. 2011 Aug 08;343:d2090
pubmed: 21824904
Vaccines (Basel). 2021 Oct 21;9(11):
pubmed: 34835152
JAMA Netw Open. 2021 Dec 1;4(12):e2137257
pubmed: 34905008
Occup Med (Lond). 2020 May 27;70(3):200-202
pubmed: 32432327
Sci Med Footb. 2021 Nov;5(sup1):2-7
pubmed: 35077316
Br J Sports Med. 2021 Jul;55(14):807-813
pubmed: 33574043
PLoS One. 2021 Aug 12;16(8):e0254798
pubmed: 34383766
J Sci Med Sport. 2022 Jan;25(1):9-14
pubmed: 34334321
Br Med J (Clin Res Ed). 1988 May 7;296(6632):1313-6
pubmed: 3133061
Br J Sports Med. 2021 Jan;55(1):62-66
pubmed: 32972979
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Scand J Med Sci Sports. 2021 Apr;31(4):936-939
pubmed: 33480037
Int J Environ Res Public Health. 2021 Apr 20;18(8):
pubmed: 33923960
Respir Res. 2020 Aug 27;21(1):224
pubmed: 32854739
Ann Intern Med. 2021 May;174(5):655-662
pubmed: 33481642